CPT 0217U Ataxia Test Reimbursement

CPT code 0217U designates a Proprietary Laboratory Analyses (PLA) test: Genomic Unity® Comprehensive Ataxia Repeat Expansion and Sequence from Variantyx Inc. The code captures a single-manufacturer laboratory assay that combines repeat expansion detection and sequencing to support genetic diagnosis of ataxia. PLA codes like 0217U matter nationally because they identify unique commercial tests with specific clinical indications, affecting coding consistency, payer coverage determinations, and laboratory billing workflows for rare neurologic disorders.

Key payers in the scope of national analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of the test, payer coverage landscape summaries, and benchmarks relevant to PLA-coded genetic assays. The publication also provides context on coding implications for laboratory claims, expected sites of service, and considerations for clinicians ordering specialized genetic diagnostics.

This report is intended for revenue cycle professionals, laboratory directors, and clinicians involved in genetic testing procurement and billing. It highlights clinical context for ataxia testing, how a PLA designation shapes administrative handling, and where to look for payer-specific coverage information. Data not available in the input is noted where applicable.

Billing Code Overview

CPT code 0217U is a Proprietary Laboratory Analyses (PLA) code that applies to a single, unique laboratory test: Genomic Unity® Comprehensive Ataxia Repeat Expansion and Sequence from Variantyx Inc. The analysis combines repeat expansion testing and sequencing to help establish a genetic diagnosis for patients with suspected ataxia.

Service type: Proprietary laboratory genetic testing (comprehensive ataxia repeat expansion and sequencing)
Typical site of service: Clinical diagnostic laboratory; specimens are submitted from outpatient clinics, neurology practices, and hospital-based providers for laboratory processing and analysis.

Clinical Context

A typical patient is an adult presenting to a neurology clinic with progressive balance impairment, unsteady gait, dysarthria, and possibly family history of neurodegenerative movement disorders. The clinician documents a workup for suspected hereditary or sporadic ataxia after neurologic exam and initial imaging (MRI brain) and metabolic screening are nondiagnostic. A blood sample is collected in the outpatient clinic or ambulatory phlebotomy lab and shipped to Variantyx Inc. for the Genomic Unity® Comprehensive Ataxia Repeat Expansion and Sequence test (0217U). Results include repeat expansion analysis and sequencing of ataxia-associated genes and inform diagnosis, genetic counseling, and management planning. Typical sites of service include outpatient neurology clinics, specialty genetic testing laboratories, and ambulatory phlebotomy centers. The clinical workflow: referral by neurologist → pre-test counseling and consent → specimen collection and ordering of 0217U → specimen shipment to the lab → laboratory processing and reporting of repeat expansion and sequencing results → disclosure of results by ordering clinician and genetic counseling as indicated.

Coding Specifications

Modifier	Description	When to Use
`00`	Unspecified	Rarely used; applies when no other modifier is appropriate for PLA reporting.

Taxonomy Code	Specialty	Notes
163W00000X	Neurology	Ordering providers commonly include neurologists diagnosing ataxia.
2085P0200X	Clinical Molecular Genetics	Laboratory directors and specialists performing genomic interpretation.
208D00000X	Clinical Laboratory	Laboratories performing testing and technical processing of `0217U`.
207RC0000X	Medical Genetics & Genomics	Medical geneticists involved in interpretation and counseling.
363L00000X	Genetic Counseling	Genetic counselors who provide pre- and post-test counseling and result disclosure.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G11.1`	Early-onset cerebellar ataxia	Genetic ataxia subtype commonly evaluated with repeat expansion and sequencing testing such as `0217U`.
`G11.3`	Hereditary spastic paraplegia	Some presentations overlap with ataxia; genetic testing can clarify diagnosis.
`G11.4`	Cerebellar ataxia, unspecified	Used when clinical features of ataxia are present but etiology is unknown; supports ordering comprehensive genetic testing.
`R27.0`	Ataxia, unspecified	Symptom code indicating ataxia warranting diagnostic genetic evaluation.
`G31.8`	Other specified degenerative diseases of nervous system	Used when neurodegenerative processes with ataxic features are suspected and genetic testing is indicated.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81479`	Unlisted molecular pathology procedure	May be used for novel or supplemental molecular testing not captured by existing PLA codes when additional analyses are required.
`88360`	Interpretation and report of molecular pathology procedures	Used by pathologists or molecular specialists to bill professional interpretation when separate from the lab technical component.
`81002`	Urinalysis, non-automated, without microscopy (qualitative)	Example of ancillary tests that may be ordered during a neurologic workup; not specific to ataxia testing but commonly available in outpatient evaluations.
`82947`	Glucose; quantitative, blood (except reagent strip)	Metabolic screening tests sometimes performed as part of broader neurologic evaluation prior to or concurrent with genetic testing.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify drug)	Represents potential supportive interventions during clinic visits; not directly tied to `0217U` but commonly present in clinic billing workflows.

OpenPayer

Summary & Overview

CPT 0217U: Genomic Unity Comprehensive Ataxia Repeat Expansion and Sequence